In conclusion, we showed that combination therapy of PD-L1 mAb plus irinotecan exerted supra-additive anti-tumor activity in a preclinical tumor model despite the fact that irinotecan induced CD8+ T cell lymphopenia. This evidence concerns the gene CD274 and neoplasm.